Elizabeth Budde, MD, PhD

Future Outlooks in the Treatment of R/R DLBCL

February 27th 2024

Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.

Additional Data Updates from ASH 2023

February 20th 2024

Jason Westin, MD, and expert panelists highlight additional clinical data presented at the 2023 American Society of Hematology annual meeting.

Treatment Sequencing of Later Line Therapies in R/R DLBCL

February 20th 2024

With the emergence of newer agents, panelists discuss their approaches to best sequence treatments for patients with R/R DLBCL.

R/R DLBCL: Safety Considerations for Bispecific Antibodies

February 13th 2024

A comprehensive overview of safety considerations for bispecific antibodies in patients treated for R/R DLBCL.

Bispecifics for Third Line Therapy of R/R DLBCL

February 13th 2024

Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.

Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting

February 6th 2024

Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.

Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL

February 6th 2024

Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.

Clinical Perspectives of CAR T in R/R Diffuse Large B-Cell Lymphoma

January 30th 2024

Experts share clinical perspectives on the use of CAR T for patients with DLBCL, in the R/R setting.

Data Updates: CAR T in the ZUMA-7 and TRANSFORM Trials for R/R DLBCL

January 30th 2024

Focused discussion on the latest updates of CAR Ts such as axi-cel and liso-cel from the ZUMA-7 and TRANSFORM trials, respectively.

The Role of CAR T-Cell Therapy in R/R DLBCL

January 29th 2024

Centering discussion on the role of CAR T-cell therapy for patients with R/R DLBCL.

Real-World Outcomes of Tafasitamab-Lenalidomide for Patients with R/R DLBCL

January 29th 2024

Panelists consider real-world outcomes for treating patients with tafasitamab-lenalidomide for R/R DLBCL.

Tafasitamab and Lenalidomide for R/R DLBCL

January 16th 2024

A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.

Treatment Selection in Second Line R/R DLBCL

January 16th 2024

Expert perspectives on treatment selection for patients with R/R DLBCL receiving second line therapy.

Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL

January 16th 2024

A brief discussion on evolving practice standards and clinical perspectives that help to inform selection of best therapy for patients with DLBCL that progress beyond initial therapy.

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

December 22nd 2023

Elizabeth Budde, MD, PhD, presents data from the 3-year follow-up from a pivotal phase II study investigating mosunetuzumab monotherapy in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies.

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients With Relapsed/Refractory LBCL: Primary Analysis of a Phase Ib/II Study

December 22nd 2023

Elizabeth Budde, MD, PhD, presents data from on mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma.

Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

December 19th 2023

Key opinion leaders on diffuse large B-cell lymphoma management provide a review first-line treatment options.

How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

October 16th 2020